Literature DB >> 28336758

Evaluation of a pharmacist-led outpatient direct oral anticoagulant service.

Emily Ashjian1, Brian Kurtz2, Elizabeth Renner2, Robert Yeshe3, Geoffrey D Barnes4.   

Abstract

PURPOSE: The impact of a pharmacist-led direct oral anticoagulant (DOAC) service on prescription appropriateness and patient adherence was simultaneously evaluated.
METHODS: In this retrospective analysis, patients age 18 years or older for whom a DOAC was prescribed from September 20, 2013, through December 31, 2014, were identified through electronic medical record review of all DOAC prescriptions within the University of Michigan Health System. Patients had their DOAC therapy managed by a pharmacist-led DOAC service or by their physician (usual care). Primary endpoints included the percentage of patients who had appropriate DOAC therapy prescribed at baseline and at follow-up appointments at 3-6 months. Secondary endpoints included mean medication possession ratios (MPRs).
RESULTS: A total of 258 patients were included in the study, with 129 in each group. Patients in the pharmacist-led DOAC service were significantly more likely to have an appropriate combination of DOAC and dosage prescribed for their indication at baseline compared with the usual care group (p = 0.009), a finding that persisted at follow up (p = 0.016). There was no significant difference between groups in the number of patients determined to have an appropriate DOAC prescribed for an approved indication (independent of dose) in the pharmacist-led service (95.3%) versus usual care (93.0%) at baseline. Patients in the pharmacist-led service had a greater mean adjusted MPR compared with the usual care group (p = 0.0014) over a median follow-up period of 248 days.
CONCLUSION: A pharmacist-led DOAC service increased appropriate dosing of DOACs at baseline and follow up as well as patient adherence to therapy.
Copyright © 2017 by the American Society of Health-System Pharmacists, Inc. All rights reserved.

Entities:  

Keywords:  DOAC; anticoagulant; apixaban; dabigatran; drug monitoring; rivaroxaban

Mesh:

Substances:

Year:  2017        PMID: 28336758     DOI: 10.2146/ajhp151026

Source DB:  PubMed          Journal:  Am J Health Syst Pharm        ISSN: 1079-2082            Impact factor:   2.637


  8 in total

1.  A pharmacist checklist for direct oral anticoagulant management: Raising the bar.

Authors:  Kori Leblanc; William M Semchuk; John Papastergiou; Blair Snow; Leilany Mandlsohn; Vinay Kapoor; Lisa M Guirguis; James D Douketis; William Geerts; David J Gladstone
Journal:  Can Pharm J (Ott)       Date:  2018-02-09

2.  Evaluation of Remote Pharmacist-Led Outpatient Service for Geriatric Patients on Rivaroxaban for Nonvalvular Atrial Fibrillation During the COVID-19 Pandemic.

Authors:  Xiaoye Li; Chengchun Zuo; Wenjing Lu; Ye Zou; Qing Xu; Xiaoyu Li; Qianzhou Lv
Journal:  Front Pharmacol       Date:  2020-08-21       Impact factor: 5.810

Review 3.  Management of venous thromboembolism with non-vitamin K oral anticoagulants: A review for nurse practitioners and pharmacists.

Authors:  Michelle Schmerge; Sally Earl; Carol Kline
Journal:  J Am Assoc Nurse Pract       Date:  2018-04       Impact factor: 1.165

4.  Optimization of DOAC management services in a centralized anticoagulation clinic.

Authors:  Katelyn W Sylvester; Alisia Chen; Andrea Lewin; John Fanikos; Samuel Z Goldhaber; Jean M Connors
Journal:  Res Pract Thromb Haemost       Date:  2022-05-05

5.  Assessing Pharmacists Knowledge and Attitude Toward the Direct Oral Anticoagulants in Qatar.

Authors:  Ahmed El-Bardissy; Hazem Elewa; Ahmed Khalil; Walid Mekkawi; Shaban Mohammed; Mohamed Kassem; Mahmoud Mohamed Alma'moon; Mohamed Abdelgelil; Yassin Eltorki; Fadl Abdelfattah A Mohamed
Journal:  Clin Appl Thromb Hemost       Date:  2020 Jan-Dec       Impact factor: 2.389

6.  Evaluation of Direct Oral Anticoagulant Prescribing in Patients With Moderate to Severe Renal Impairment.

Authors:  Clara Ting; Megan Rhoten; Jillian Dempsey; Hunter Nichols; John Fanikos; Christian T Ruff
Journal:  Clin Appl Thromb Hemost       Date:  2021 Jan-Dec       Impact factor: 2.389

7.  Drug-related problem characterization and the solved status associated factor analysis in a pharmacist-managed anticoagulation clinic.

Authors:  Ju-Chieh Wung; Hsin-Chung Lin; Chia-Chen Hsu; Chia-Chieh Lin; Szu-Yu Wang; Shih-Lin Chang; Yuh-Lih Chang
Journal:  PLoS One       Date:  2022-08-15       Impact factor: 3.752

8.  Implementation of warfarin to direct oral anticoagulant conversion initiative in pharmacist-run anticoagulation clinics during COVID-19 pandemic.

Authors:  Katie Kish; Sanela Lekic
Journal:  J Am Coll Clin Pharm       Date:  2021-06-08
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.